Please enable JavaScript to continue using this application.

Compare $DSGN vs $GYRE | Chartloom

Compare

$DSGN vs $GYRE

Design Therapeutics Inc · Gyre Therapeutics Inc

DSGN

Design Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Compare $DSGN vs $GYRE

Comparing Design Therapeutics Inc and Gyre Therapeutics Inc

DSGNDesign Therapeutics Inc

GYREGyre Therapeutics Inc

DSGNDesign Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

28.0%

52W performance

67.9%

FCF yield

-7.6%

GYREGyre Therapeutics Inc

Market cap

$643M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

16.8%

YTD performance

3.4%

52W performance

-3.6%

FCF yield

-2.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DSGN

GYRE

Detailed metrics comparison

DSGN

Design Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Market Cap

DSGN$728M

GYRE$643M

Enterprise Value

DSGN$715M

GYRE$600M

Price

DSGN$11.65

GYRE$7.04

P/E Ratio

DSGNN/A

GYREN/A

P/S Ratio

DSGN0.00x

GYRE5.39x

EV/Sales

DSGN0.00x

GYRE5.03x

EV/EBITDA

DSGN0.00x

GYRE286.88x

P/B Ratio

DSGN3.83x

GYRE5.78x

P/FCF Ratio

DSGNN/A

GYREN/A

EV/FCF

DSGN-12.96x

GYRE-35.74x

PEG Ratio

DSGNN/A

GYREN/A

Forward P/E (NTM)

DSGNN/A

GYREN/A

Forward P/S (NTM)

DSGNN/A

GYREN/A

Revenue (TTM)

DSGN$0

GYRE$119M

Revenue Growth (YoY)

DSGNN/A

GYRE16.8%

Forward Rev Growth

DSGN1360.4%

GYRE21.1%

Gross Margin (TTM)

DSGN0.0%

GYRE94.3%

Operating Margin (TTM)

DSGN0.0%

GYRE0.0%

EBITDA Margin (TTM)

DSGN0.0%

GYRE-8.5%

Net Margin (TTM)

DSGN0.0%

GYRE-15.5%

FCF Margin (TTM)

DSGNN/A

GYRE-14.1%

Net Income (TTM)

DSGN$-71M

GYRE$-18M

FCF (TTM)

DSGN$-55M

GYRE$-17M

EPS (TTM)

DSGN-$1.13

GYRE-$0.18

ROE (TTM)

DSGN-3403.0%

GYRE-1584.0%

ROA (TTM)

DSGN-3205.0%

GYRE-1014.0%

ROIC (TTM)

DSGN-3403.0%

GYRE-1584.0%

Cash

DSGN$13M

GYRE$43M

Debt

DSGN$0

GYRE$0

Net Cash/Debt

DSGN$13M

GYRE$43M

Current Ratio (TTM)

DSGN18.86x

GYRE4.26x

Quick Ratio (TTM)

DSGN18.61x

GYRE3.64x

Debt/Equity (TTM)

DSGN0.00x

GYRE0.00x

Debt/Assets (TTM)

DSGN0.0%

GYRE0.0%

Interest Coverage (TTM)

DSGNN/A

GYREN/A

Net Debt/EBITDA (TTM)

DSGN0.00x

GYRE0.00x

Beta

DSGN1.72

GYRE2.46

52W Performance

DSGN67.9%

GYRE-3.6%

YTD Performance

DSGN28.0%

GYRE3.4%

% from 52W High

DSGN-32.5%

GYRE-25.3%

% from 52W Low

DSGN120.6%

GYRE29.4%

Asset Turnover (TTM)

DSGN0.00x

GYRE0.70x

FCF Yield (TTM)

DSGN-7.6%

GYRE-2.6%

Earnings Yield (TTM)

DSGN-9.7%

GYRE-2.9%

Dividend Yield (TTM)

DSGNN/A

GYREN/A

Rule of 40

DSGN0.0

GYRE2.8

EV/GP/RG

DSGNN/A

GYRE0.23

Ticker research

View DSGN research View GYRE research

Metric	DSGN Design Therapeutics Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$728M	$643M
Enterprise Value	$715M	$600M
Price	$11.65	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	5.39x
EV/Sales	0.00x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	3.83x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.96x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$119M
Revenue Growth (YoY)	N/A	16.8%
Forward Rev Growth	1360.4%	21.1%
Profitability
Gross Margin (TTM)	0.0%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-8.5%
Net Margin (TTM)	0.0%	-15.5%
FCF Margin (TTM)	N/A	-14.1%
Net Income (TTM)	$-71M	$-18M
FCF (TTM)	$-55M	$-17M
EPS (TTM)	-$1.13	-$0.18
ROE (TTM)	-3403.0%	-1584.0%
ROA (TTM)	-3205.0%	-1014.0%
ROIC (TTM)	-3403.0%	-1584.0%
Financial Health
Cash	$13M	$43M
Debt	$0	$0
Net Cash/Debt	$13M	$43M
Current Ratio (TTM)	18.86x	4.26x
Quick Ratio (TTM)	18.61x	3.64x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.72	2.46
52W Performance	67.9%	-3.6%
YTD Performance	28.0%	3.4%
% from 52W High	-32.5%	-25.3%
% from 52W Low	120.6%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.70x
FCF Yield (TTM)	-7.6%	-2.6%
Earnings Yield (TTM)	-9.7%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	2.8
EV/GP/RG	N/A	0.23
Ticker research	View DSGN research	View GYRE research

Valuation

P/S Ratio

DSGN

0.00x

GYRE

5.39x

EV/FCF

GYRE

-35.74x

DSGN

-12.96x

Growth & revenue

Revenue Growth TTM

GYRE

16.8%

Forward Revenue Growth

DSGN

1360.4%

GYRE

21.1%

Profitability & performance

Gross Margin

GYRE

94.3%

DSGN

0.0%

ROE

GYRE

-1584.0%

DSGN

-3403.0%

FCF Yield %

GYRE

-2.6%

DSGN

-7.6%

52-Week Performance

DSGN

67.9%

GYRE

-3.6%

Detailed metrics comparison

DSGN

Design Therapeutics Inc

GYRE

Gyre Therapeutics Inc

Market Cap

DSGN$728M

GYRE$643M

Enterprise Value

DSGN$715M

GYRE$600M

Price

DSGN$11.65

GYRE$7.04

P/E Ratio

DSGNN/A

GYREN/A

P/S Ratio

DSGN0.00x

GYRE5.39x

EV/Sales

DSGN0.00x

GYRE5.03x

EV/EBITDA

DSGN0.00x

GYRE286.88x

P/B Ratio

DSGN3.83x

GYRE5.78x

P/FCF Ratio

DSGNN/A

GYREN/A

EV/FCF

DSGN-12.96x

GYRE-35.74x

PEG Ratio

DSGNN/A

GYREN/A

Forward P/E (NTM)

DSGNN/A

GYREN/A

Forward P/S (NTM)

DSGNN/A

GYREN/A

Revenue (TTM)

DSGN$0

GYRE$119M

Revenue Growth (YoY)

DSGNN/A

GYRE16.8%

Forward Rev Growth

DSGN1360.4%

GYRE21.1%

Gross Margin (TTM)

DSGN0.0%

GYRE94.3%

Operating Margin (TTM)

DSGN0.0%

GYRE0.0%

EBITDA Margin (TTM)

DSGN0.0%

GYRE-8.5%

Net Margin (TTM)

DSGN0.0%

GYRE-15.5%

FCF Margin (TTM)

DSGNN/A

GYRE-14.1%

Net Income (TTM)

DSGN$-71M

GYRE$-18M

FCF (TTM)

DSGN$-55M

GYRE$-17M

EPS (TTM)

DSGN-$1.13

GYRE-$0.18

ROE (TTM)

DSGN-3403.0%

GYRE-1584.0%

ROA (TTM)

DSGN-3205.0%

GYRE-1014.0%

ROIC (TTM)

DSGN-3403.0%

GYRE-1584.0%

Cash

DSGN$13M

GYRE$43M

Debt

DSGN$0

GYRE$0

Net Cash/Debt

DSGN$13M

GYRE$43M

Current Ratio (TTM)

DSGN18.86x

GYRE4.26x

Quick Ratio (TTM)

DSGN18.61x

GYRE3.64x

Debt/Equity (TTM)

DSGN0.00x

GYRE0.00x

Debt/Assets (TTM)

DSGN0.0%

GYRE0.0%

Interest Coverage (TTM)

DSGNN/A

GYREN/A

Net Debt/EBITDA (TTM)

DSGN0.00x

GYRE0.00x

Beta

DSGN1.72

GYRE2.46

52W Performance

DSGN67.9%

GYRE-3.6%

YTD Performance

DSGN28.0%

GYRE3.4%

% from 52W High

DSGN-32.5%

GYRE-25.3%

% from 52W Low

DSGN120.6%

GYRE29.4%

Asset Turnover (TTM)

DSGN0.00x

GYRE0.70x

FCF Yield (TTM)

DSGN-7.6%

GYRE-2.6%

Earnings Yield (TTM)

DSGN-9.7%

GYRE-2.9%

Dividend Yield (TTM)

DSGNN/A

GYREN/A

Rule of 40

DSGN0.0

GYRE2.8

EV/GP/RG

DSGNN/A

GYRE0.23

Ticker research

View DSGN research View GYRE research

Metric	DSGN Design Therapeutics Inc	GYRE Gyre Therapeutics Inc
Market & Valuation
Market Cap	$728M	$643M
Enterprise Value	$715M	$600M
Price	$11.65	$7.04
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	5.39x
EV/Sales	0.00x	5.03x
EV/EBITDA	0.00x	286.88x
P/B Ratio	3.83x	5.78x
P/FCF Ratio	N/A	N/A
EV/FCF	-12.96x	-35.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$119M
Revenue Growth (YoY)	N/A	16.8%
Forward Rev Growth	1360.4%	21.1%
Profitability
Gross Margin (TTM)	0.0%	94.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-8.5%
Net Margin (TTM)	0.0%	-15.5%
FCF Margin (TTM)	N/A	-14.1%
Net Income (TTM)	$-71M	$-18M
FCF (TTM)	$-55M	$-17M
EPS (TTM)	-$1.13	-$0.18
ROE (TTM)	-3403.0%	-1584.0%
ROA (TTM)	-3205.0%	-1014.0%
ROIC (TTM)	-3403.0%	-1584.0%
Financial Health
Cash	$13M	$43M
Debt	$0	$0
Net Cash/Debt	$13M	$43M
Current Ratio (TTM)	18.86x	4.26x
Quick Ratio (TTM)	18.61x	3.64x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.72	2.46
52W Performance	67.9%	-3.6%
YTD Performance	28.0%	3.4%
% from 52W High	-32.5%	-25.3%
% from 52W Low	120.6%	29.4%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.70x
FCF Yield (TTM)	-7.6%	-2.6%
Earnings Yield (TTM)	-9.7%	-2.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	2.8
EV/GP/RG	N/A	0.23
Ticker research	View DSGN research	View GYRE research